World Class Research at NYU
Dr. Galloway says that his team travels the world to accomplish their mission to bring their knowledge to remote corners.
"There is a shortage of heart surgical procedures outside of the U.S., Europe and Australia. The humanitarian goal of medicine is to be able to provide these services to as many people as possible that need them. That requires that we train people to do as well with the procedures as we do here in the U.S."
The venerable NYU Medical Centers also host visiting surgeons about twice a month. They are treated to a full television set-up of the operating arena where they can see and hear everything that goes on.
"We train about 50 cardiac surgeons that come in to watch our new techniques every year," said Dr. Galloway. "In academic medicine, we see what's good and new and hope to perfect it and disseminate the information throughout the United States and the world, so that healthcare can progress."
Due to the fact that NYU Medical Center is a premiere facility where research routinely makes its way to the patient population, it receives about 75 applications from hopeful medical interns for only three highly-coveted spots for residencies in their cardiothoracic surgery program. Only the finest candidates succeed in getting in the door.
"We look at the overall background of the applicant, their skills-their drive, and how creative they are," Dr. Galloway said.
The research team is currently conducting molecular-level biological research. Within the next two or three years, Dr. Galloway says they will be able to genetically manipulate the signaling pathways of body parts by inserting different DNA into the sequence with a keen eye always trained on the best outcome for the patient. The goal is to achieve more durable 30-year results with fewer side effects.
"Whenever you do anything to the body, there is a certain response," Dr. Galloway explained. "If you take a vein out of the leg, which is used to low pressure, and you make it act as a heart artery, which is high pressure, the body's fats, lipids, and scar tissue response are called into action. We're trying to understand the process at the molecular level and change the response of the internal signals to lessen the likelihood of late failure."
The NYU research team is also currently working on methods to facilitate and simplify coronary bypass surgery.
"We're perfecting ways so that patients can be operated on without heart and lung machines and the need for any blood," said Dr. Galloway, who added that the mission of the medical center is to always lower the risks and side effects of any operation they perform.
"At the molecular level, we want to slow the entire course of heart disease and arteriosclerosis," said Dr. Galloway.
At the end of the day, Dr. Galloway says he hopes to be able to reflect on a concrete contribution to humanity and the satisfaction that his patients are leading normal, healthy lives.
Last Page || Next Page
Med Update is a publication of Lionheart Ventures, L.L.C. and is distributed by The New York Times. Lionheart Ventures, L.L.C., does not endorse the physician opinions expressed in Med Update. Lionheart Ventures, L.L.C. encourages discussion with your personal physician prior to seeking additional medical advice. The New York Times did not participate in the writing, editing, or photography of Med Update. Lionheart Ventures, L.L.C. exclusively owns all rights to Med Update. Photography is by Keith Weller. Please direct all inquiries regarding being featured in future issues of Med Update to Scott Simpson at (630) 718-9600 or (888) 962-4500
|
New York University Medical Center is a remarkably original voice in teaching technological advances in heart surgery around the world. Their team is the harbinger of new treatments for cardiovascular disease and like the Johnny Appleseeds of heart surgery trends; the NYU team travels the world, teaching their perfected state-of-the-art less traumatic surgical methods. Being the primary purveyors of the new minimally invasive operating techniques, surgeons from around the world are eager to soak up the collective NYU surgical team's knowledge. The NYU team frequently travels to Europe, and in October, they plan to teach mitral valve repair and minimally invasive surgery at China's Fu Wai Hospital in Beijing. "One of our missions as an academic medical center is to first push the edges of medical technology and beneficial breakthroughs, and to then teach them," said Dr. Aubrey Galloway, professor of surgery and director of cardiac surgical research at NYU Medical Center. "Healthcare should not be looked at as a competitive marketing issue, rather how we can deliver the best care in this country, and throughout the world." |
|
"There is a shortage of heart surgical procedures outside of the U.S., Europe and Australia. The humanitarian goal of medicine is to be able to provide these services to as many people as possible that need them. That requires that we train people to do as well with the procedures as we do here in the U.S."
The venerable NYU Medical Centers also host visiting surgeons about twice a month. They are treated to a full television set-up of the operating arena where they can see and hear everything that goes on.
"We train about 50 cardiac surgeons that come in to watch our new techniques every year," said Dr. Galloway. "In academic medicine, we see what's good and new and hope to perfect it and disseminate the information throughout the United States and the world, so that healthcare can progress."
Due to the fact that NYU Medical Center is a premiere facility where research routinely makes its way to the patient population, it receives about 75 applications from hopeful medical interns for only three highly-coveted spots for residencies in their cardiothoracic surgery program. Only the finest candidates succeed in getting in the door.
"We look at the overall background of the applicant, their skills-their drive, and how creative they are," Dr. Galloway said.
The research team is currently conducting molecular-level biological research. Within the next two or three years, Dr. Galloway says they will be able to genetically manipulate the signaling pathways of body parts by inserting different DNA into the sequence with a keen eye always trained on the best outcome for the patient. The goal is to achieve more durable 30-year results with fewer side effects.
"Whenever you do anything to the body, there is a certain response," Dr. Galloway explained. "If you take a vein out of the leg, which is used to low pressure, and you make it act as a heart artery, which is high pressure, the body's fats, lipids, and scar tissue response are called into action. We're trying to understand the process at the molecular level and change the response of the internal signals to lessen the likelihood of late failure."
The NYU research team is also currently working on methods to facilitate and simplify coronary bypass surgery.
"We're perfecting ways so that patients can be operated on without heart and lung machines and the need for any blood," said Dr. Galloway, who added that the mission of the medical center is to always lower the risks and side effects of any operation they perform.
"At the molecular level, we want to slow the entire course of heart disease and arteriosclerosis," said Dr. Galloway.
At the end of the day, Dr. Galloway says he hopes to be able to reflect on a concrete contribution to humanity and the satisfaction that his patients are leading normal, healthy lives.
Last Page || Next Page
Med Update is a publication of Lionheart Ventures, L.L.C. and is distributed by The New York Times. Lionheart Ventures, L.L.C., does not endorse the physician opinions expressed in Med Update. Lionheart Ventures, L.L.C. encourages discussion with your personal physician prior to seeking additional medical advice. The New York Times did not participate in the writing, editing, or photography of Med Update. Lionheart Ventures, L.L.C. exclusively owns all rights to Med Update. Photography is by Keith Weller. Please direct all inquiries regarding being featured in future issues of Med Update to Scott Simpson at (630) 718-9600 or (888) 962-4500